Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
复制标题
DOI：
10.1371/journal.pone.0201846
复制
发表时间：
2018
期刊：
影响因子：
3.7
通讯作者：
Kuwano H
中科院分区：
文献类型：
--
作者：
Kurozumi S;Matsumoto H;Inoue K;Tozuka K;Hayashi Y;Kurosumi M;Oyama T;Fujii T;Horiguchi J;Kuwano H
术前内分泌预后指数 (PEPI) 可预测绝经后雌激素受体 (ER) 阳性乳腺癌女性使用芳香酶抑制剂 (AI) 新辅助内分泌治疗 (NAE) 后的生存率，无论人表皮生长因子受体 2 (HER2) 状态如何。虽然孕酮受体（PgR）也是 ER 阳性乳腺癌的预后因素，但在最初的 PEPI 评分系统中，PgR 状态并未被视为预后因素。在这项研究中，我们研究了修改后的 PEPI（包括 PgR 状态 (PEPI-P)）作为绝经后 ER 阳性和 HER2 阴性乳腺癌患者 NAE 后预后因素的效用。我们入组了 107 名患有侵袭性 ER 阳性和 HER2 阴性乳腺癌的患者，接受依西美坦治疗 ≥4 个月作为 NAE。我们最初评估了 PEPI 并比较了各组之间的生存率。此外，我们通过生存分析获得了 PgR 的有效截止值。然后，我们评估了 PEPI-P 的生存意义。 50% 的 PgR 染色率是预测无复发生存 (RFS) 和癌症特异性生存 (CSS) 的最显着截止值。 PEPI 是一个重要的预后因素；此外，PEPI-P 是 RFS 和 CSS 最重要的预后指标。 PEPI-P 是绝经后 ER 阳性和 HER2 阴性乳腺癌患者使用 AI 进行 NAE 后生存的有效预后指标。这种改良的 PEPI 可能有助于 NAE 后绝经后 ER 阳性和 HER2 阴性乳腺癌的治疗决策。
The preoperative endocrine prognostic index (PEPI) predicts survival after neoadjuvant endocrine therapy (NAE) using aromatase inhibitors (AIs) for women with postmenopausal estrogen receptor (ER)-positive breast cancer irrespective of the human epidermal growth factor receptor 2 (HER2) status. Although the progesterone receptor (PgR) is also a prognostic factor for ER-positive breast cancer, the PgR status was not considered a prognostic factor in the original PEPI scoring system. In this study, we investigated the utility of a modified PEPI including the PgR status (PEPI-P) as a prognostic factor after NAE for postmenopausal patients with ER-positive and HER2-negative breast cancer. We enrolled 107 patients with invasive ER-positive and HER2-negative breast cancer treated with exemestane for ≥4 months as NAE. We initially assessed PEPI and compared survival between the groups. Additionally, we obtained an effective cutoff for PgR through survival analysis. Then, we assessed the survival significance of PEPI-P. A PgR staining rate of 50% was the most significant cutoff for predicting recurrence-free survival (RFS) and cancer-specific survival (CSS). PEPI was a significant prognostic factor; moreover, PEPI-P was the most significant prognostic indicator for RFS and CSS. PEPI-P is a potent prognostic indicator of survival after NAE using AIs for postmenopausal patients with ER-positive and HER2-negative breast cancer. This modified PEPI may be useful for therapeutic decision-making regarding postmenopausal ER-positive and HER2-negative breast cancer after NAE.
登录
查看更多内容
DOI：
10.1093/jnci/djn309
发表时间：
2008-10-01
期刊：
Journal of the National Cancer Institute
影响因子：
--
作者：
Ellis MJ;Tao Y;Luo J;A'Hern R;Evans DB;Bhatnagar AS;Chaudri Ross HA;von Kameke A;Miller WR;Smith I;Eiermann W;Dowsett M
通讯作者：
Dowsett M
影响因子：
3.9
作者：
Akashi-Tanaka, Sadako;Omatsu, Mutsuko;Fukutomi, Takashi
通讯作者：
Fukutomi, Takashi
影响因子：
45.3
作者：
Smith, IE;Dowsett, M;Walsh, G
通讯作者：
Walsh, G
影响因子：
8.8
作者：
Purdie, C. A.;Quinlan, P.;Jordan, L. B.;Ashfield, A.;Ogston, S.;Dewar, J. A.;Thompson, A. M.
通讯作者：
Thompson, A. M.
影响因子：
3.8
作者：
Kurozumi S;Matsumoto H;Hayashi Y;Tozuka K;Inoue K;Horiguchi J;Takeyoshi I;Oyama T;Kurosumi M
通讯作者：
Kurosumi M